-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

Benzinga·08/06/2026 17:19:30
Listen to the news
Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.